Martha Buitrago is an Infectious Disease physician affiliated with Idaho State University. OpenAlex indexes 12 publications with 506 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3614 Washington Pkwy
Idaho Falls, ID 834047573
Telephone
208-535-8400Provider last certified this registry record 5 Oct 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- La Jolla Pharmaceutical CompanyProgram year20241 payment
- AbbVie Inc.Program year20232 payments
- La Jolla Pharmaceutical CompanyProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
81%Tetracycline-class Drug19.7%Doxycycline Hyclate82%Doxycycline Monohydrate18%Part D<11 patientsFirst-generation cephalosporins12.6%Cephalexin100%Part D≥38 patients+ 10 more classes in this area
Blood & clotting
17.1%Salt solutions17.1%Sodium Chloride100%Part D<11 patientsSensory organs
1.9%Aminoglycoside Antibacterial1.9%Gentamicin Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease
Emerging infectious diseases
2019 - Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection
Antimicrobial Agents and Chemotherapy
2015 - Susceptibility of<i>Clostridium difficile</i>isolates from a Phase 2 clinical trial of cadazolid and vancomycin in<i>C. difficile</i>infection
Journal of Antimicrobial Chemotherapy
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”